Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 study of AZ-3102

Next Previous
Search
Trial Profile

Phase 3 study of AZ-3102

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 14 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nizubaglustat (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Registrational; Therapeutic Use
  • Sponsors Azafaros

    • Most Recent Events

    • 08 Jan 2025 According to an Azafaros media release, the company's Clinical Trial Application (CTA) for two global Phase 3 studies investigating the drug's efficacy and safety in GM1/GM2 gangliosidoses and Niemann-Pick Type C (NPC) was approved by multiple European countries. Company expects to initiate this two trials in Q2, 2025.
    • 19 Nov 2024 According to an Azafaros media release, the company will host a satellite symposium on February 4, 2025 at 12:15, which will outline the company's Phase 3 global development plans for nizubaglustat. These upcoming global Phase 3 studies for GM1 and GM2 gangliosidoses and Niemann-Pick-disease-type-C (NPC) are set to be conducted across major regions including the United States, Europe, Latin America, and other select countries.
    • 10 Sep 2024 According to an Azafaros media release, the company planes to initiate Phase 3 pivotal studies in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top